Healthcare Industry News: Optical Biopsy
News Release - June 16, 2008
SpectraScience Adds Industry Veteran to Executive TeamSAN DIEGO, June 16 (HSMN NewsFeed) -- SpectraScience, Inc. (OTC Bulletin Board: SCIE ), a San Diego based medical devices company today announced the appointment of its new Vice President of Sales, Christopher Jackson, who has held senior sales positions at Adeza Biomedical Specialty Laboratories, Medigene and most recently at Neomatrix, Inc.
"Chris brings to SpectraScience more than 24 years of sales and marketing experience in the medical device and lab services industries," said Jim Hitchin, CEO of SpectraScience. "We are excited to add Chris to our team and expect him to significantly impact our sales and marketing efforts. He has a demonstrated ability to grow sales for developing businesses. At Adeza, Chris was integral to expanding its sales force from 4 to 75 people, and from less than $750 thousand in sales to more than $44 million. His performance at the other firms he has worked with has been equally impressive. Bringing Chris on board gives our company a critical resource in helping us realize our vision of becoming the premier cancer screening device company in the marketplace."
Chris Jackson added "I am impressed with SpectraScience's technology and much of my decision to join the company is based on the opportunity to make a real impact in the cancer screening market with a more effective device."
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT® Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA clearance for sale in the U.S. and the CE Mark for the European Union, the WavSTAT system is the first commercially available product that incorporates this innovative and patented technology for clinical use. The Company's LUMA® cervical imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods currently available.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.